Dosimetry of 223Ra-chloride: Dose to normal organs and tissues

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 2, 2013, Pages 207-212

  Lassmann, Michael ^a   Nosske, Dietmar ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

Author keywords

223Ra Chloride; Alpharadin ; Bone metastases; Castration resistant prostate cancer; Dosimetry

Indexed keywords

RADIUM CHLORIDE RA 223; RADIOPHARMACEUTICAL AGENT; RADIUM; RADON;

ADRENAL GLAND; ALPHA RADIATION; ARTICLE; BETA RADIATION; BLADDER WALL; BONE; BONE MARROW; BONE PAIN; BRAIN; BREAST; COLON; COMPARATIVE STUDY; DOSE CALCULATION; DOSIMETRY; ESOPHAGUS; HUMAN; KIDNEY; LARGE INTESTINE; LIVER; LUNG; MUSCLE; OVARY; PALLIATIVE THERAPY; PANCREAS; RADIOIMMUNOTHERAPY; RESPIRATORY SYSTEM; SKIN; SMALL INTESTINE; SPLEEN; STOMACH WALL; TESTIS; THYMUS; THYROID GLAND; UTERUS; CHEMISTRY; KINETICS; MALE; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIOMETRY; RISK; TIME; TISSUE DISTRIBUTION;

ALPHA PARTICLES; BONE AND BONES; BONE MARROW; HUMANS; KINETICS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIUM; RADON; RISK; TIME FACTORS; TISSUE DISTRIBUTION;

MLCS; MLOWN;

EID: 84874106208     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2265-y     Document Type: Article

References (19)

1. 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12:6250s-7s.
2. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94.
3. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451-9.
4. Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48:678-86.
5. Lewington V, Lamey R, Staudacher K, Vogelzang N. Radium-223 chloride: radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases. J Nucl Med 2012;53(Suppl 1):222.
6. ICRP. Publication 67: Age-dependent doses to members of the public from intake of radionuclides: part 2 ingestion dose coefficients. Ann ICRP 1992;22.
7. 224Ra-radium chloride: dosimetry and risk considerations. Radiat Environ Biophys 2002;41:173-8.
8. Salmon PL, Onischuk YN, Bondarenko OA, Lanyon LE. Alpha-particle doses to cells of the bone remodeling cycle from alpha-particle-emitting bone-seekers: indications of an antiresorptive effect of actinides. Radiat Res 1999;152:S43-7.
9. Leggett RW. A generic age-specific biokinetic model for calcium-like elements. Radiat Prot Dosimetry 1992;41:183-98.
10. ICRP. Publication 71: Age-dependent doses to members of the public from intake of radionuclides: part 4 inhalation dose coefficients. Ann ICRP 1995;25.
11. ICRP. Publication 110: Adult reference computational phantoms. Ann ICRP 2009;2.
12. ICRP. Publication 30 (part 1): Limits for intakes of radionuclides by workers. Ann ICRP 1979;2.
13. ICRP. Publication 100. Human alimentary tract model for radiological protection. Ann ICRP 2006;36:1-2.
14. Howell RW, Goddu SM, Narra VR, Fisher DR, Schenter RE, Rao DV. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiat Res 1997;147:342-8.
15. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010;51:311-28.
16. ICRP. Publication 103: The 2007 recommendations of the International Commission on Radiological Protection. Ann ICRP 2007;2007:37.
17. Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934-40.
18. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol 2012;57:3207-22.
19. 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun 2012;33:726-32.